Neuroscience

Global Neuroscience Antibodies and Assays Market Predicted to Witness Sustainable Evolution in Future 2020-2026 | Thermo Fisher, Abcam, Bio-Rad,…

This report studies the GlobalNeuroscience Antibodies and AssaysMarket with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Neuroscience Antibodies and Assays Market in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting. A Neuroscience Antibodies and Assays Market provides an extensive view of size; trends and shape have been developed in this report to identify factors that will exhibit a significant impact in boosting the sales of Neuroscience Antibodies and Assays Market in the near future.The global Neuroscience Antibodies and Assays Market report presents the detailed extensive study regarding the market in an efficient way by dividing the whole market into different segments [Product, Applications, End-Users, and Major Regions] on the basis of type and form of product offered by the industries, product processing methods and techniques, end-user applications, and others. Not only this, but the market study also categorizes the market based on theregions [Latin America, North America, Asia Pacific, Middle & East Africa, and Europe]. The report also comprises the market growth forecast information calculated by the professional on the basis of previous information about the market and its-related industries as well as the current trends followed by the market. The report also provides the markets CAGR forecast for the specific period of the upcoming time.Business report explains the effect of various segments to the growth of the target market. Also this report provide detail analysis of the Target market, with the help of Further, analytical framework involves PEST analysis, and POTERS five analysis of the target market.

Request for Sample Report @https://www.indexmarketsresearch.com/report/neuroscience-antibodies-and-assays-market/448974/#requestforsample

Global Market portal aims to provide reports like these in order to draw the attention of many of the clients wanting to extrapolate some of the vital details of the Neuroscience Antibodies and Assays market on a global scale. The Neuroscience Antibodies and Assays market dossier talks about the market segmentation created on the basis of product type, governments norms, key industrial players, competitive landscapes, applications, end-user, topological players, and more. The report presents a demand for individual segment in each region. It demonstrates variousProduct Type Segments {Consumables, Instruments}andApplications Segments {Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers}. The current report data simulates the market status and investment gains or losses in a very illustrative manner so as to provide the analyzed data in a very refreshed format.

Competitive Analysis:The report provides a list of all the key players in the Neuroscience Antibodies and Assays market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product development, research, and development, and also provides revenue shares, company overview, and recent company developments to remain competitive in the market.

Neuroscience Antibodies and Assays Market Main Competitors are :Thermo Fisher, Abcam, Bio-Rad, Merck, Cell Signaling Technology, Genscript, Rockland Immunochemicals, BioLegend, Santa Cruz Biotechnology, Roche, Siemens

The main objectives of the research report elaborate the overall market overview on market dynamics, historic volume and value, robust market methodology, current and future trends, Porters Five Forces Analysis, upstream and downstream industry chain, new technological development, cost structure, government policies and regulations, etc. Major companies, company overview, financial data, products and services, strategy analysis, key developments market competition, industry competition structure analysis, SWOT Analysis, etc. Alternatively, it also includes factors that are poised to challenge the market growth over the forecast period. These factors are expected to reveal certain hidden trends that aid in the better understanding of the market over the forecast period. Continue reading this report. All these sections of the report have been analyzed in detail to reach at accurate and trustworthy conclusion of the future trajectory. This also includes an overview section that mentions the definition, classification, and primary applications of the product/service to provide larger context to the audience to this report. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

The Neuroscience Antibodies and Assays report provides wide-ranging statistical analysis of the markets continuous positive developments, capacity, production, production value, cost/profit, supply/demand and import/export about Industry. The report is prepared with a group of graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years. With this precise report, it can be easily understood the growth potential, revenue growth, product range, and pricing factors related to the Neuroscience Antibodies and Assays market. Further, the report highlights key hurdles and latest growth trends which are accepted by leading players and are part of the competitive spectrum of this business. The Neuroscience Antibodies and Assays market research report provides a comprehensive analysis of this business segment and provides essential insight into the factors influencing revenue generation as well as industry growth. Apart from the regulatory outlook, the document also includes a detailed assessment of the regional scope of the market. Further, the report includes detailed SWOT analysis and explains the driving factors of the market. Latest improvements in the industry have been integrated in the report by anticipating the future perspective of the market. It also states about the various marketing channels that are coming up in the global market.

TOC of Neuroscience Antibodies and Assays Market Report Includes:

Major Players:The report provides company profiling for a decent number of leading players of the global Neuroscience Antibodies and Assays market. It brings to light their current and future market growth taking into consideration their price, gross margin, revenue, production, areas served, production sites, and other factors.

Neuroscience Antibodies and Assays Market Dynamics:The report shares important information on influence factors, market drivers, challenges, opportunities, and market trends as part of market dynamics.

Global Neuroscience Antibodies and Assays Market Forecast:Readers are provided with production and revenue forecasts for the global Neuroscience Antibodies and Assays market, production and consumption forecasts for regional markets, production, revenue, and price forecasts for the global Neuroscience Antibodies and Assays market by type, and consumption forecast for the global Neuroscience Antibodies and Assays market by application.

Regional Market Analysis:It could be divided into two different sections: one for regional production analysis and the other for regional consumption analysis. Here, the analysts share gross margin, price, revenue, production, CAGR, and other factors that indicate the growth of all regional markets studied in the report.

Neuroscience Antibodies and Assays Market Competition:In this section, the report provides information on competitive situation and trends including merger and acquisition and expansion, market shares of the top three or five players, and market concentration rate. Readers could also be provided with production, revenue, and average price shares by manufacturers.

This exclusive study addresses key questions for stakeholders in the Neuroscience Antibodies and Assays Market:* What are the key developments anticipated to take place in the Neuroscience Antibodies and Assays market during the period of 2020-2026?* What are the crucial strategies adopted by players operating in the Neuroscience Antibodies and Assays market?* Which end-user segment will remain a key contributor to the growth of the Neuroscience Antibodies and Assays market?* What are the important trends stimulating the growth of the Neuroscience Antibodies and Assays market?* Which application segment will bode lucrative growth opportunities for the Neuroscience Antibodies and Assays market?

Browse full report @https://www.indexmarketsresearch.com/report/neuroscience-antibodies-and-assays-market/448974/

Factors such as industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The report also incorporates premium quality data figures associated with financial figures of the industry including market size (in USD), expected market size growth (in percentage), sales data, revenue figures and more. This might enable readers to reach quicker decisions with data and insights at hand. To provide information on competitive landscape, this report includes detailed profiles of Neuroscience Antibodies and Assays Market key players. For each player, product details, capacity, price, cost, gross and revenue numbers are given. Their contact information is provided for better understanding.

In conclusion, Neuroscience Antibodies and Assays market report provides global, economy, competitive landscape analysis. It also studies the market revenue and status of key manufacturers. Neuroscience Antibodies and Assays market report decodes the sales, price, and gross margin analysis and global sales, price, growth rate, marketing trader or distributor analysis.

Request customized copy of Neuroscience Antibodies and Assays reportWe are grateful to you for reading our report. If you wish to find more details of the report or want a customization, contact us. You can get a detailed of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Us @sales@indexmarketsresearch.com

Read this article:
Global Neuroscience Antibodies and Assays Market Predicted to Witness Sustainable Evolution in Future 2020-2026 | Thermo Fisher, Abcam, Bio-Rad,...

Neuroscience

Neuroscience Market Growth Opportunities, Key Players, and Threads Analysis – PRnews Leader

Global Neuroscience Market: Overview

The global neuroscience market is expected to witness a promising growth in the next few years. The rising level of competition among the leading players and the rising focus on the development of new products are likely to offer promising growth opportunities throughout the forecast period. The research study on the global neuroscience market offers a detailed overview, highlighting the key aspects that are expected to enhance the growth of the market in the near future. The key segmentation and the competitive landscape of the market have also been mentioned at length in the research study.

Global Neuroscience Market: Key Trends

The rising trade of neuroscience consumables and devices for the diagnostics and imaging purpose of nervous system and brain is projected to encourage the growth of the global neuroscience market in the next few years. The function and structure of the nervous system and neurological disorders in several countries such as Russia and Poland is likely to enhance the growth of the overall market in the coming few years.

Request a PDF Brochure https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=49641

Moreover, the rising awareness among consumers regarding to the benefits of advanced neuroscience devices, including combination of other imaging devices is projected to accelerate the growth of the global neuroscience market in the next few years.

Global Neuroscience Market: Market Potential

The rising government spending on the healthcare infrastructure, especially in developed regions is one of the major factors estimated to encourage the growth of the global neuroscience market in the next few years. The rising health spending in the U.S. is predicted to rise substantially, which is another key factor that is likely to enhance the market growth in the near future. In addition to this, the high adoption of new technologies and the rising spending on the research and development activities are expected to generate potential growth opportunities for the market players in the next few years.

Request for Analysis of COVID19 Impact on Neuroscience Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=49641

Global Neuroscience Market: Regional Outlook

Among the key regional segments, the Middle East and Africa is expected to hold a large share of the global neuroscience market in the next few years. The rapid development of the medical sector is predicted to enhance the growth of the Middle East and Africa market for neuroscience in the coming few years. Furthermore, Asia Pacific is estimated to witness a healthy growth in the coming years.

The rising geriatric population and the rising incidences of CNS disorders are predicted to encourage the growth of the market in the near future. Europe and North America are estimated to observe a promising growth in the next few years.

Global Neuroscience Market: Competitive Analysis

The global market for neuroscience is competitive in nature and is projected to witness a high level of competition among the key players in the next few years. The growing focus on the research and development activities and innovations is projected to support the growth of the overall market in the next few years. Moreover, the rising mergers and acquisitions and collaborations is likely to enhance the growth of the market in the near future.

Pre Book Neuroscience Market Research https://www.transparencymarketresearch.com/checkout.php?rep_id=49641&ltype=S

Some of the key players operating in the neuroscience market across the globe are Plexon Inc., Alpha Omega, Femtonics Ltd., Kendall Research Systems LLC, Doric Lenses Inc., Siemens Healthineers, GE Healthcare, Laserglow Technologies, Neuralynx, Thomas RECORDING GmbH, Mediso Ltd., TRIFOIL IMAGING, Prizmatix, and Neurotar.

More Trending Reports by Transparency Market Research

Life Science Reagents Market: http://www.prnewswire.com/news-releases/technological-advancements-to-drive-significant-growth-in-the-life-science-reagents-market-from-2019-to-2027-states-tmr-301025999.html

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Visit link:
Neuroscience Market Growth Opportunities, Key Players, and Threads Analysis - PRnews Leader

Neuroscience

The Neuroscience Market To Get Back To The Holistic Mode With A CAGR Of 7.2% – TechnoWeekly

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

With healthy CAGR of 6.4%, the globalneuroscience marketis likely to grow from US$ 301.6 Mn in 2016 to US$ 520.8 Mn by 2025 end. This growth is mainly fuelled by advancement in neuroimaging and increasing R & D in neuroinformatics. Neuroscience Market: Global Industry Analysis (2012-2016)and Forecast (2017-2025),is the new publication of Persistence Market Research that focuses on merger and acquisition, strategic collaborations and technology, and technology transfer agreements, which play a vital role in the global neuroscience market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/13390

Company Profiles

North America and Europe are expected to dominate the global neuroscience market in the assessed period of 8-years that is between 2017 and 2025.

Global Neuroscience Market: Relevance and Impact of Factors

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/13390

Global Neuroscience Market: Forecast by Component Type

On the basis of component type, the global neuroscience market is segmented into instrument, software and services. Instrument segmented is sub-segmented into MRI imaging systems and neuromicroscopy, while services segmented divided into consulting services, installation services and maintenance services.

Instrument segment dominated the global neuroscience market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. Instrument segment is the most attractive segment, with attractiveness index of 2.6 over the forecast period.

Instrument segment was valued at US$ 221.6 Mn in 2016 and is projected to be valued at US$ 408.1 Mn in 2025 growing at a CAGR of 7.2% during the forecast period. This segment is expected to accounts for high revenue contribution to the global neuroscience market as compared to software and services segments over the forecast period.

Software segment is expected to be the second most lucrative segment in the global neuroscience market, with attractiveness index of 0.3 during the forecast period. This segment was accounted for 15.4% value share in 2017 which is expected to drop down to 12.9 % revenue share in 2025.

Global Neuroscience Market: Forecast by End User

On the basis of end user, global neuroscience market is segmented into hospitals, diagnostic laboratories, research institutes, and academic institutes.

Diagnostics laboratory segment is expected to be the second most lucrative segment in the global neuroscience market by 2025 end. However, in terms of CAGR and revenue share, hospitals segment is expected to lead he market throughout the estimated period. In 2025, hospital segment is likely to grab 40.2% market share in 2025, expanding at a robust CAGR of 7.3% during the estimated period.

Research institutes segment is expected to be the least attractive segment in the global neuroscience market, with attractiveness index of 0.7 during the forecast period.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/13390

Global Neuroscience Market: Forecast by Region

On the basis of region, global neuroscience market is segmented into North America, Latin America, Europe, APAC and MEA. North America dominated the global neuroscience market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period.

North America is projected to be the most attractive market with attractiveness index of 2.3 during the forecast period. Europe is expected to be the second most lucrative market, with attractiveness index of 1.1 respectively during the forecast period.

Europe Neuroscience market accounted for 23.9% share in 2017 and is projected to account for 23.1% share by 2025 end.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

More:
The Neuroscience Market To Get Back To The Holistic Mode With A CAGR Of 7.2% - TechnoWeekly

Neuroscience

Microglia, the brain’s trash collector cells, may play larger role in brain health, may reveal clues to disease treatments – National Institute on…

Microglia are a minority among brain cells, but a new study in mice is adding to the evidence that these trash collector cells may have a mightier role in brain health and disease, and could provide clues to new treatment targets for neurodegenerative diseases such as Alzheimers. Funded in part by NIA and published in Nature, this latest research suggests there is a microglia-driven negative feedback mechanism that is modifying how neurons act.

Neurons, which make up about 50% of brain cells, have long been viewed as the drivers of brain processes, such as thoughts and behavior. Meanwhile microglia, representing only about 10% of brain cells, have been seen as the clean-up crew. For their job as the brains immune cells, microglia remove dying neurons, prune synapses, and generally support the survival of neurons.

A research team at the Icahn School of Medicine at Mount Sinai performed a series of experiments in mice, including the removal of microglia from specific brain regions. Led by Anne Schaefer, M.D., Ph.D., Professor of Neuroscience and Psychiatry, and a 2012 NIH Directors New Innovator Award Recipient, researchers compared neuronal responses to different insults and controls. When the microglia were removed, at first the neurons were fine, but then went haywire, showing a seizure response to insults.

The findings show a circuit between neurons and microglia that involve the molecule adenosine triphosphate (ATP). When neurons are active, they release ATP, which attracts microglia. The microglia in turn break down ATP into forms of adenosine, which suppress synaptic transmission and neuron activity. Without microglia, or when microglia dont respond to ATP, the seizure response kicks in with excessive neuronal activity.

The researchers also looked at this circuit in an Alzheimers disease mouse model and saw the same seizure response. They hypothesize that this type of microglia-induced neuromodulation may go awry in neurodegenerative diseases, including Alzheimers and Huntingtons, and contribute to increases in neuron excitability and behavior changes that are associated with those disorders. Targeting the microglia system could potentially be a therapeutic protecting the brain from abnormal activation seen in neurodegenerative diseases.

As a next step, Dr. Schaefer and colleagues are starting to investigate the epigenetic mechanisms of microglia activation during aging and its contributions to neurodegenerative diseases. NIA recently awarded the Icahn School of Medicine at Mount Sinai a $2.99 million grant (number RF1AG068558) toward this effort targeting microglial epigenetic regulators specific to inflammation.

This research was funded in part by NIA grants R01AG045040, U01AG058635, and T32AG049688.

These activities relate to NIHs AD+ADRD Research Implementation Milestone 2.A, "Create new research programs that use data-driven, systems-based approaches to integrate the study of fundamental biology of aging with neurobiology of aging and research on neurodegeneration, AD and AD-related dementias to better understand the mechanism(s) of vulnerability and resilience in AD across all levels of biologic complexity (from cellular to population level) and to gain a deeper understanding of the complex biology and integrative physiology of healthy and pathologic brain aging." They also relate to Milestone 2.B, "Establish new research programs that employ data-driven, systems-based approaches to understand the interaction between peripheral systems (in particular: immune, metabolic, microbiome) and the brain and the impact of this interaction on brain aging and neurodegeneration. These efforts should integrate human and animal model research and characterize the extent to which molecular (epigenomic, transcriptomic and metabolomic) variation identified in peripheral tissues can be used as a proxy for inter-individual variation in the trajectories of brain aging, AD and AD-related dementias."

Reference: Badimon A, et al. Negative feedback control of neuronal activity by microglia. Nature. 2020;586(7829):417-423. doi: 10.1038/s41586-020-2777-8.

Read more from the original source:
Microglia, the brain's trash collector cells, may play larger role in brain health, may reveal clues to disease treatments - National Institute on...

Neuroscience

The Idea of the Brain by Matthew Cobb review lighting up the grey matter – The Guardian

Is your brain a computer? Is mine? Is Boris Johnsons? And if so, where is the tech support hotline? Brains were once conceived of as marvellous clockwork, pneumatic or hydraulic devices, but for the last 70 years we have been encouraged to think of our wetware as our own modern technology. But the brain doesnt contain any digital switches and was not designed for the convenience or edification of any external user. The idea that it is a computer is just the latest in a series of metaphors, and one that is looking increasingly threadbare.

So runs the argument of the zoologist Matthew Cobbs rich and fascinating book, which divides neatly into two parts, or hemispheres. The first is a cultural and scientific history of how previous ages thought of the brain. It was a collection of cavities through which animal spirits flowed; then it became a machine, which was a breakthrough idea: perhaps you could investigate it as you might any machine, by breaking it down into its constituent parts and seeing what they do. This suggestion had to be invented, being first put forward in the mid-17th century by the Danish anatomist (and bishop) Nicolaus Steno.

A century later, electricity was the fashionable thing, so natural philosophers began to theorise that perhaps the animal spirits sloshing around in the brain were in fact a kind of electric fluid. Perhaps, suggested one, the brain was very like a galvanic battery. By the mid-19th century, nerves were inevitably compared to telegraph wires and the brain to a completely electrical system.

Around the same time, the craze for phrenology produced detailed maps of how mental functions were localised in certain parts of the brain, which were incorrect, although the principle of (partial) localisation of brain function remains valid. Evolutionary theory meanwhile threw a spanner into the works by highlighting our utter ignorance of how a messily evolved lump of grey blancmange can give rise to subjective experience, thought, and On the Origin of Species itself.

It cant be emphasised enough how complete our ignorance still is on this point, as Cobb reminds us. We understand many more things today about the brains neurons and how they operate together, but we still lack the faintest beginning of a clue as to why and how they produce your awareness that you are reading this sentence. Why should they? Why arent we all just unconscious robots? Cobb does pay attention throughout to the writings of modern philosophers on this topic, though he can at times seem to be conflating two very different views: the mainstream idea that conscious states are caused only by brain states (somehow), and the much more radical idea that conscious states literally are just brain states: that the two things are identical. The latter view, usually called eliminative materialism, has the virtue of magicking away the alleged problem of consciousness entirely, though at some cost in plausibility.

Leading the reader on through the history of cybernetics and early computers, Cobb arrives at the beginning of modern neuroscience in the 1950s. The rest of the book is a colourful history of that research, which celebrates extraordinary advances such as brain imaging, the understanding of neurotransmitters, and optogenetics (the ability to activate neurons with light), while consistently pointing out the huge limitations that remain in our current understanding.

What will be the next grand metaphor about the brain? Impossible to say, because we need to wait for the next world-changing technology. But in the mean time, Cobb suggests, the computer metaphor might be doing more harm than good. After all, he notes rightly: Metaphors shape our ideas in ways that are not always helpful.

Indeed, next time you are tempted to say that you are in two minds about some question, remember the experiments he describes here with subjects who had the link between their brain hemispheres severed (to address acute epilepsy): such people, it seemed, now had two entirely independent minds in one head, each perceiving and knowing things the other did not. Its impossible to imagine what that is like. But the response of the psychologist William Estes to the research is still wonderfully apt: Great, now we have two things we dont understand.

The Idea of the Brain by Matthew Cobb is published by Profile (30). To order a copy go to guardianbookshop.com. Delivery charges may apply.

See the original post here:
The Idea of the Brain by Matthew Cobb review lighting up the grey matter - The Guardian

Neuroscience

Cartographers of the brain – UCI News

Thanks to Xiangmin Xu and his team at the UCI School of Medicines Center for Neural Circuit Mapping, lazy eye, Alzheimers and other neurological diseases could become a thing of the past.

Opened earlier this year, the unit focuses on basic neuroscience research, advancing knowledge of the brain by defining mechanisms and pathways that underlie neurodevelopmental, neuropsychiatric and neurodegenerative disorders.

Our 30 to 40 investigators can join forces to tackle large-scale research projects with potentially far-reaching impact, including mechanistic studies ofAlzheimers disease, says director Xu, professor of anatomy & neurobiology.

The facilitys first project supported in part by the National Institutes of Health was on amblyopia, more commonly known as lazy eye. Stemming from unequal visual development early in life, it causes the brain to ignore signals from the weaker eye, resulting in a loss of neural connectivity and further impairing sight in that eye.

By subcutaneously administering subanesthetic ketamine, an antidepressant traditionally used for pain management, Xu and his researchers were able to reverse the effects of amblyopia and reactivate adult neural connectivity. In August, their findings were published in Current Biology, and while further testing is required to determine the full implications of this discovery, it could have a significant impact on the treatment of this disorder.

Additionally, with a $3.8 million award from the National Institute on Aging, center members are studying molecular changes in the brain caused by Alzheimers. Using mouse models that mimic the neurodegenerative disease, theyre exploring how the epigenome of major cell types, including neurons and non-neuronal cells such as astrocytes and microglia, shapes hippocampal circuit activity and behaviors during Alzheimers pathogenesis.

The research involves viral tracing, a method of implanting a harmless virus into a specific neuron in the brain and tracking its movement along neural pathways to determine cellular connectivity. Tracers travel along the interconnected pathways and, as these connections become increasingly damaged, plot the diseases progression and its effect on memory loss.Viral tracers are important tools for neuroanatomical mapping and will allow researchers to specifically target affected neurons with possible gene-editing or -repairing treatments in the future.

Our goal is to reveal the molecular changes that occur during the course of Alzheimers, impacting learning and memory, and identify a route toward early detection and new drug therapies for the disease, Xu says.

A critical component of the Center for Neural Circuit Mapping is the creation of a viral production facility to disseminate these novel molecular tools for amblyopia, Alzheimers and other potential diseases to the global neuroscience community.

Currently, there is no cure for Alzheimers disease, Xu says. And with millions of people, including 5.5 million Americans, affected by this debilitating condition, its increasingly critical that we develop superior early diagnostic techniques and new treatment strategies to care for them.

While the center is focused on cutting-edge breakthroughs in neuroscience, its staff is not limited to professors and postdoctoral students. The unit is active in UCIs Undergraduate Research Opportunities Program, and before the coronavirus outbreak, more than 20 undergrads worked there. Theyre trained by postdocs to better prepare them for careers in biomedical research. They also employ methods common in computer science and engineering, gaining wide-ranging experience in real-world situations.

The Center for Neural Circuit Mapping provides a strong infrastructure and many resources for investigators to develop new tools to further studies, Xu says, and it will help UCI researchers obtain federal funding for our critical work.

See the article here:
Cartographers of the brain - UCI News

Neuroscience

Study Shows Biocept’s Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and…

SAN DIEGO, Nov. 20, 2020 /PRNewswire/ --Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study analyzing cerebrospinal fluid (CSF) samples in patients with primary lung or breast cancer with either brain or leptomeningeal disease. The findings indicate that Target Selector CSF assays are a viable and sensitive platform for circulating tumor cell (CTC) detection and molecular analysis compared to the current standard of care, CSF cytology, which is typically used to establish or confirm leptomeningeal disease when imaging findings are suspicious or equivocal. CSF cytology has limited sensitivity and provides no additional information needed for target therapy choice.

The results were discussed yesterday in a poster presentation by Santosh Kesari, MD, PhD, Chair and Professor, Department of Translational Neurosciences, Director of Neuro-oncology at the Pacific Neuroscience Institute and John Wayne Cancer Institute, at the Society for Neuro-Oncology's SNO2020 Virtual Conference on November 19, 2020.

"Once a tumor has metastasized to the brain, CTCs and circulating tumor DNA (ctDNA) can be found in the cerebrospinal fluid," said Dr. Kesari. "This prospective study compared the sensitivity of CTC detection and molecular analysisof Biocept's Target Selector CSF assays to cytology (microscopic examination of conventional CSF cytology slide preps). This study highlights the potential of CSF-based diagnostics for longitudinal monitoring cancers in the central nervous system."

"Our Target Selector testing is a minimally invasive, cost-effective strategy to simultaneously confirm metastasis to the brain, while also assessing cancer biomarkers in order to qualify a patient for potential targeted therapy options," said Michael Nall, President and CEO of Biocept. "Identifying CTCs and actionable biomarkers with Target Selector can help to confirm and monitor central nervous system involvement when clinically suspected, without the risk of complications associated with surgical biopsies, which are often impossible in these cases.

"This the second major scientific conference in less than two months to accept study results from Target Selector testing in cerebrospinal fluid for presentation," added Mr. Nall. "We view neuro-oncology as an area where our technology is uniquely suited to answer questions posed by treating physicians, and we are appreciative of the Society of Neuro-Oncology's recognition of our Target Selector testing."

About the SNO2020 Virtual Conference

The Society for Neuro-Oncology exists to advance multi-disciplinary brain tumor research, education, and collaboration to drive discovery and improve patient care. Over 2,600 neuro-oncology professionals are expected to register for the SNO2020 Virtual Conference being held November 19-21, 2020. More information can be found at soc-neuro-onc.org.

About Biocept

Biocept, Inc.is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. Additionally,Bioceptis offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic.For more information, please visit http://www.biocept.com.

Forward-Looking Statements Disclaimer StatementThis release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding neuro-oncology being an area where Biocept's technology is uniquely suited to answer questions posed by treating physiciansthe ability of Biocept's platform to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Investor Contact:LHA Investor Relations Jody CainJcain@lhai.com310-691-7100

View original content to download multimedia:http://www.prnewswire.com/news-releases/study-shows-biocepts-assays-are-viable-and-sensitive-for-detecting-tumor-cells-and-biomarkers-in-the-cerebrospinal-fluid-of-patients-with-breast-and-lung-cancer-that-has-metastasized-to-the-central-nervous-system-301177929.html

SOURCE Biocept, Inc.

Originally posted here:
Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and...

Neuroscience

Suffering in silence: two-thirds of older adults say they won’t treat their depression – Newswise

Newswise SALT LAKE CITY, November 16, 2020 - A new nationwide poll, the GeneSight Mental Health Monitor, shows that nearly two-thirds (61%) of Americans age 65 or older who have concerns about having depression will not seek treatment. In fact, nearly 1 in 3 (33%) seniors who are concerned they might be suffering from depression believe they can "snap out" of it on their own.

"The 'pull yourself up by your bootstraps' mindset of some seniors and reluctance to talk about mental health are hindering them from getting the help they need - especially now when the pandemic is having an enormous impact on the mental health of older Americans," said Dr. Mark Pollack, chief medical officer of Myriad Neuroscience, makers of the GeneSight test. "People will seek treatment for conditions like heart disease, high blood pressure or diabetes. Depression is no different. It is an illness that can and should be treated."

Yet, while depression is a condition that needs to be treated:

"In my experience, there is a commonly held view that depression is a normal part of aging; it is not," said Dr. Parikshit Deshmukh, CEO and medical director of Balanced Wellbeing LLC in Oxford, Florida, which provides psychiatric and psychotherapy services to nursing and assisted living facilities. "I've found older adults have a very difficult time admitting that they have depression. When they do acknowledge it, they are still reluctant to start treatment for a wide variety of reasons."

Depression remains a taboo topic among older Americans, despite about one-third of those over the age of 65 who are concerned they have depression recognizing that depression has interfered with their relationships and their ability to enjoy activities.

"There is such a stigma about depression among people my age," said Carmala Walgren, a 74-year-old resident of New York. "I am proof that you do not have to accept living with depression. Although it may not be easy to find treatment that helps you with your symptoms without causing side effects, it is certainly worth it."

Walgren's doctor used information from the results of her GeneSight test, a genetic test that identifies potential gene-drug interactions for depression medications, to help inform Walgren's medication selection.

"The GeneSight test made such a difference in my life," said Walgren. "My doctor has used the test results to find medications that helped me."

###

The GeneSight Mental Health Monitor is a nationwide survey of US adults conducted by Acupoll from August 12-September 27, 2020. The survey was conducted among a statistically representative sample of US adults age 18+, including a US representative sample of adults age 65 and older. The margin of error in survey results for those Age 65+ who are concerned they may have depression but have not been diagnosed is +/-5%.

For more information on older adults and depression, please visit genesight.com/olderadult

Myriad Neuroscience

Myriad Neuroscience is a business unit of Myriad Genetics, Inc. (NASDAQ: MYGN). Through its GeneSight Psychotropic test, Myriad Neuroscience provides information to healthcare providers about their patient's genetic variations, which may impact how they metabolize or respond to certain psychiatric medications. Learn more at genesight.com/about-myriad-neuroscience/

The GeneSight Test

The GeneSight Psychotropic test from Myriad Neuroscience is the category-leading pharmacogenomic test for depression medications. The GeneSight test can help inform doctors about genes that may impact how patients metabolize or respond to certain psychiatric medications. It has been given to more than one million patients by tens of thousands of clinicians to provide genetic information that is unique to each patient. It supplements other information considered by a doctor as part of a comprehensive medical assessment. Learn more at GeneSight.com.

Excerpt from:
Suffering in silence: two-thirds of older adults say they won't treat their depression - Newswise

Neuroscience

Brain conditions, mental and neurological alike – Open Access Government

Brain conditions, mental and neurological alike, account for a large burden on the European population. In 2017, 307.9 million neurological disease diagnoses alone were counted in the EU28 countries 540.3 million neurological diseases in the WHO European region. Across Europe, neurological disorders alone accounted for an estimated 21% of all deaths. (1) Additionally, psychiatric conditions such as depression, anxiety disorders and alcohol and drug use disorders, affect more than one in six people across the European Union in any given year. (2) It was estimated conservatively that every year, 27% of the total adult EU population are affected by a mental disorder, amounting to over 82.7 million affected persons. (3)

Despite this high prevalence, numerous conditions of the brain are shrouded in mystery and remain without disease-modifying treatments or cures. Compared to other disease areas, the pace of innovation in this field has traditionally been hindered by multiple factors, starting with the complexity of the brain itself.

Continued research and development in the brain space are crucial. Despite considerable advances in basic neuroscience, the complete understanding of brain functions and the mechanisms behind brain disorders remains a future perspective, mainly due to the complexity of the system itself. As a consequence, a large number of brain conditions remain without a disease-modifying therapy or cure and both fundamental and translational research is still highly needed. Furthermore, failure rates in drug development are higher in neuroscience than in other areas and new treatments take, on average, longer to reach the market than in other disease areas.

Understanding the brain, how to prevent brain ill-health and how to treat and cure brain diseases, mental and neurological, are the only solutions to help society cope. Prevention begins by raising awareness, developing resources and providing proper support, but concrete solutions can only be attained through well-supported and well-coordinated research efforts.

We need to change the pace: we need to innovate, remaining conscious that in brain science, innovation must be considered as a broad and inclusive concept: from novel approaches and ideas of brain researchers to translational research, to novel policy recommendations. To shift momentum, innovation in the brain needs to open to all possible prospects and through a multi-stakeholder approach.

Major developments in non-communicable diseases have demonstrated the immense benefits to be gained from a dynamic collaboration between all stakeholders committed to progress, encompassing patient organisations, academics, scientists, medical experts and industry.

Discoveries and advances in basic neuroscience are the prerequisites for describing the normal functioning of the nervous system and improving our understanding of the aetiology and pathophysiology of brain disorders. Researchers play a key role yet without patient engagement, public and policymaker support, pharmaceutical R&D, entrepreneurial inventions, and more, the brain space remains stagnant and fragmented. Without these key players working together, no progress can be made. Enhanced multi-stakeholder engagement in the brain ecosystem is needed to foster dialogue, exchange knowledge, accelerate investment in research and innovation and facilitate treatment and cure development.

The EU-funded European Brain Research Area (EBRA) project (4), coordinated by the European Brain Council in partnership with the Human Brain Project, ERA-NET NEURON and the EU Joint Programme on Neurodegenerative Disease Research (JPND) is a prime example of the European Commissions vision for improved facilitation of research across Europe. The project in itself was designed as a catalysing initiative for brain research stakeholders to streamline and better coordinate brain research across Europe while fostering global initiatives.

Patient organisations are continuously mobilising for better awareness and calls for inclusion. EU-funded projects like MULTI-ACT (5) exist to create pathways for responsible research for and with the patients the research ultimately impacts. Collaboration in the field of brain disorders is less prevalent than in other fields such as oncology for example, public-private partnerships, which bring together top academic institutions and the pharmaceutical industry, are still relatively underdeveloped. (6)

The brain community has many examples of successful collaborations and more continue to exist. Through projects like the above, community-building activities such as the Brain Innovation Days (7) and continued policy work, improved solutions are in sight. Ongoing work in the field of innovation and demonstrating the value of innovation are currently underway to help create an enabling environment to foster investment in innovation in brain disorders in Europe and propose concrete avenues to remove existing barriers.

European Institutions can play a key role in the improvement of key policies in health and research. A long-term research ecosystem that helps support interdisciplinary networks, cross-border initiatives, health data infrastructures, robust collaboration, medical education and regulatory flexibility is necessary. In order to tackle our major health challenges, we need to develop a coordinated and strategic approach to plan (brain) health research, linked to the need of wider health and research policy.

To reduce the societal impact of neurological disorders and mental ill-health, European authorities must devise and implement a plan to tackle brain health in an integrated and comprehensive manner in cooperation with all EU Member States. Acknowledgement of urgency and prioritisation are needed to make sure that brain disorders remain high on the health policy agenda at the country level and globally.

References

(1) The Lancet Public Health, VOLUME 5, ISSUE 10, E551-E567, OCTOBER 01, 2020, The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017; Deuschl, G, et al. https://doi.org/10.1016/S2468-2667(20)30190-0

(2) OECD/European Union (2018), Health at a Glance: Europe 2018: State of Health in the EU Cycle, OECD Publishing, Paris/European Union, Brussels, https://doi.org/10.1787/health_glance_eur-2018-en

(3) Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jnsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79. doi: 10.1016/j.euroneuro.2011.07.018. PMID: 21896369.

(4) European Brain Research Area, https://www.ebra.eu

(5) MULTI-ACT, http://www.multiact.eu

(6) Phillips AG, Hongaard-Andersen P, Moscicki RA, Sahakian B, Quiron R, Krishnan KR, Race T. (2014) Proceedings of the 2013 CINP Summit: innovative partnerships to accelerate CNS drug discovery for improved patient care. Int J Neuropsychopharmacol. 18(3). pii: pyu100. doi: 10.1093/ijnp/pyu100.

(7) https://www.braininnovationdays.eu

Editor's Recommended Articles

Read the original:
Brain conditions, mental and neurological alike - Open Access Government

Neuroscience

Hyperbaric oxygen treatments in healthy adults can reverse the aging process, finds study – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Nov 19 2020

A new study from Tel Aviv University (TAU) and the Shamir Medical Center in Israel indicates that hyperbaric oxygen treatments (HBOT) in healthy aging adults can stop the aging of blood cells and reverse the aging process. In the biological sense, the adults' blood cells actually grow younger as the treatments progress.

The researchers found that a unique protocol of treatments with high-pressure oxygen in a pressure chamber can reverse two major processes associated with aging and its illnesses: the shortening of telomeres (protective regions located at both ends of every chromosome) and the accumulation of old and malfunctioning cells in the body. Focusing on immune cells containing DNA obtained from the participants' blood, the study discovered a lengthening of up to 38% of the telomeres, as well as a decrease of up to 37% in the presence of senescent cells.

The study was led by Professor Shai Efrati of the Sackler School of Medicine and the Sagol School of Neuroscience at TAU and Founder and Director of the Sagol Center of Hyperbaric Medicine at the Shamir Medical Center; and Dr. Amir Hadanny, Chief Medical Research Officer of the Sagol Center for Hyperbaric Medicine and Research at the Shamir Medical Center. The clinical trial was conducted as part of a comprehensive Israeli research program that targets aging as a reversible condition.

The paper was published in Aging on November 18, 2020.

For many years our team has been engaged in hyperbaric research and therapy - treatments based on protocols of exposure to high-pressure oxygen at various concentrations inside a pressure chamber. Our achievements over the years included the improvement of brain functions damaged by age, stroke or brain injury.

In the current study we wished to examine the impact of HBOT on healthy and independent aging adults, and to discover whether such treatments can slow down, stop or even reverse the normal aging process at the cellular level."

Professor Shai Efrati, Sackler School of Medicine and the Sagol School of Neuroscience at TAU

The researchers exposed 35 healthy individuals aged 64 or over to a series of 60 hyperbaric sessions over a period of 90 days. Each participant provided blood samples before, during and at the end of the treatments as well as some time after the series of treatments concluded. The researchers then analyzed various immune cells in the blood and compared the results.

The findings indicated that the treatments actually reversed the aging process in two of its major aspects: The telomeres at the ends of the chromosomes grew longer instead of shorter, at a rate of 20%-38% for the different cell types; and the percentage of senescent cells in the overall cell population was reduced significantly - by 11%-37% depending on cell type.

"Today telomere shortening is considered the 'Holy Grail' of the biology of aging," Professor Efrati says. "Researchers around the world are trying to develop pharmacological and environmental interventions that enable telomere elongation. Our HBOT protocol was able to achieve this, proving that the aging process can in fact be reversed at the basic cellular-molecular level."

"Until now, interventions such as lifestyle modifications and intense exercise were shown to have some inhibiting effect on telomere shortening," Dr. Hadanny adds. "But in our study, only three months of HBOT were able to elongate telomeres at rates far beyond any currently available interventions or lifestyle modifications. With this pioneering study, we have opened a door for further research on the cellular impact of HBOT and its potential for reversing the aging process."

Source:

Journal reference:

Hachmo, Y., et al. (2020) Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells : a prospective trial. Aging. doi.org/10.18632/aging.202188.

Read the rest here:
Hyperbaric oxygen treatments in healthy adults can reverse the aging process, finds study - News-Medical.Net